Oulin Biotech's net profit attributable to parent in 2025 is expected to be 22.26 million yuan, a year-on-year increase of 7.2%.

2026-04-05 11:06:48

On March 30, Oulin Biotech (688319) released its 2025 annual report. The company’s operating revenue was 704 million yuan, up 19.6% year over year; net profit attributable to shareholders was 22.26 million yuan, up 7.2% year over year; non-recurring items net profit attributable to shareholders was 9.91 million yuan, down 11.4% year over year; net operating cash flow was 105 million yuan, up 1184.1%; and EPS (fully diluted) was 0.0548 yuan.

Among them, in the fourth quarter, the company’s operating revenue was 197 million yuan, down 2.5% year over year; net profit attributable to shareholders was a loss of 25.22 million yuan, down 250.7% year over year; non-recurring items net profit attributable to shareholders was a loss of 30.13 million yuan, down 361.7% year over year; and EPS was -0.0621 yuan.

As of the end of the fourth quarter, the company’s total assets were 2.02B yuan, up 12.0% from the end of the previous year; shareholders’ net assets attributable to shareholders were 904 million yuan, down 2.3% from the end of the previous year.

In the company’s operating activities in 2025, it continued to advance the R&D and commercialization of innovative vaccines. Its core strategy is focused on two major areas: “superbacterial vaccines” and “adult vaccines.” The company has successfully achieved commercial sales of three vaccines, with the adsorbed tetanus toxoid vaccine as a cornerstone product. Its market share has remained among the leading positions in the industry, providing stable cash flow for the company’s continued innovation and development.

In the management discussion and analysis section, the company mentioned that R&D expenditures accounted for 28.20% of operating revenue. In the reporting period, the Phase III clinical trial for the recombinant Staphylococcus aureus vaccine had completed the enrollment of all subjects, and it is expected to complete data unblinding in the first half of 2026. In addition, the company is actively expanding the adult vaccine market and developing a quadrivalent/trivalent influenza virus split vaccine based on cell culture technology.

A massive flow of information and precise interpretation—available on the Sina Finance APP

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes